Applied Imaging (NASDAQ:AICXD)
Historical Stock Chart
From Jun 2019 to Jun 2024
Applied Imaging Announces Collaboration With the University of
Vermont College of Medicine
SAN JOSE, Calif., May 26 /PRNewswire-FirstCall/ -- Applied Imaging Corp.
(NASDAQ:AICXD) and the University of Vermont (UVM) College of Medicine, today
announced a collaboration between Applied Imaging's wholly-owned subsidiary,
CTC, Inc. (CTC) and UVM to further develop and clinically validate proprietary
technology to detect, quantify and characterize circulating tumor cells in the
blood of cancer patients. David Krag, M.D., S.D. Ireland Professor of Surgical
Oncology, will lead the program at UVM.
Tumor cells are known to be shed from cancerous tumors (including breast,
ovarian, colorectal, prostate and lung cancers) into the blood. These cells
contain critical information about the status and progression of the disease.
With an initial focus on breast cancer, CTC is developing a system for
detecting and evaluating these tumor cells in a routine blood sample. CTC's
approach incorporates a unique cell selection technology coupled with Applied
Imaging's proprietary Ariol(R) automated cell imaging system.
"Dr. Krag is a well-recognized leader in the application of new technologies
that address important health care initiatives and we believe that this
collaboration will help enormously in our goal of developing
clinically-validated technology for improving the lives of breast cancer
patients," commented Diane Day, Corporate Vice President of Applied Imaging and
General Manager of CTC Inc. "We have already installed an Ariol(R) system in
Dr. Krag's laboratory."
"I am very excited about the prospects for this partnership, because our
translational research programs have been largely focused on making
improvements to breast cancer care, including the development and application
of radio-guided surgical resection of sentinel nodes," said Dr. Krag. "It is
the undetected cancer cells that remain in a patient following definitive
surgery, radiation, and systemic therapy that often grow and lead to the demise
of the patient. The more we understand about these remaining cells, the closer
we are to curing breast cancer. We believe that this research holds great
promise for improving breast cancer management, and look forward to working
closely with CTC to perfect technology that helps to satisfy the critical needs
in this area."
Timely assessment of patient status through the analysis of circulating tumor
cells has the potential to aid the oncologist in improving patient care. It
could also provide the potential for earlier detection of disease. According to
the American Cancer Society (ACS), breast cancer is the leading cause of death
for American women between the ages of 35 and 54. ACS forecasts that there
will be over 192,000 new, invasive breast cancer cases in the U.S. this year
alone. Invasive breast cancer causes about 40,000 deaths per year.
Code: AICXG
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier
of automated imaging and image analysis systems for the detection and
characterization of chromosomes and molecular markers in genetics and pathology
laboratories. The Company develops, manufactures and markets a range of
scanning and image analysis systems for both conventional (brightfield) and
fluorescent microscopic analysis of cellular and tissue specimens. Products
are sold to hospital laboratories, cancer centers, prenatal clinics and
research institutions for both research and clinical purposes. The Company has
installed over 3,500 of its systems in over 1000 laboratories in more than 60
countries around the world. Beyond its core business, through its wholly-owned
subsidiary, CTC, Inc., the Company is also developing a system for the
detection, quantification and characterization of tumor cells in the blood of
cancer patients. More information about Applied Imaging can be found at
http://www.aicorp.com/.
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the ability of CTC, Inc. to develop proprietary technology that
detects circulating tumor cells for, among other applications, the management
of breast cancer patients; and the success of the collaboration with University
of Vermont. Forward looking statements address matters that are subject to a
number of risks, uncertainties and other factors, which are detailed in the
Company's periodic filings with the Securities and Exchange Commission. Such
risks, uncertainties and other factors include, but are not limited to, CTC's
ability to research, develop, patent and commercialize new technology to detect
and characterize circulating tumor cells in blood. The forward-looking
statements in this news release are made as of May 26, 2005, and Applied
Imaging is under no obligation to revise or update these statements.
CCG Investor Relations
Crocker Coulson, President
10960 Wilshire Blvd., Suite 2050
Los Angeles, CA 90024
310-231-8600, Ext. 103
Applied Imaging Corp.
Diane Day, General Manager, CTC, Inc.
120 Baytech Drive
San Jose, CA 95134
(408) 719-6400
DATASOURCE: Applied Imaging Corp.
CONTACT: Crocker Coulson, President of CCG Investor Relations,
+1-310-231-8600, ext. 103, ; or Diane Day, General
Manager of CTC, Inc., +1-408-719-6400, ; both for Applied
Imaging Corp.
Web site: http://www.aicorp.com/